Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Original) A compound of formula (I):



(I)

wherein:

R^1 represents hydrogen, -C_{1-6} alkyl, -C_{1-6} alkoxy, -C_{3-8} cycloalkyl, -C_{1-6} alkyl-C_{3-8} cycloalkyl, aryl, heterocyclyl, heteroaryl, -C_{1-6} alkyl-aryl, -C_{1-6} alkyl-heteroaryl, -C_{1-6} alkyl-heterocyclyl, -aryl-aryl, -aryl-heteroaryl, -aryl-heterocyclyl,- heteroaryl-aryl, -heteroaryl-heteroaryl, -heteroaryl-heterocyclyl, -heterocyclyl-aryl, -heterocyclyl-heteroaryl, -heterocyclyl-heterocyclyl,

wherein R^1 may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, $COOR^{15}$, cyano, -C_{1-6} alkyl-cyano, nitro, oxo, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C_{1-6} alkyl (optionally substituted by a $COOR^{15}$ group), C_{2-6} alkenyl (optionally substituted by a $COOR^{15}$ group), C_{2-6} alkynyl (optionally substituted by a $COOR^{15}$ group), C_{1-6} alkoxy (optionally substituted by a $COOR^{15}$ group), pentafluoroethyl, C_{1-6} alkoxy, C_{2-6} alkenoxy, aryl, arylC_{1-6} alkyl, -CO-aryl (optionally substituted by a halogen atom), -CO-heteroaryl, -C_{1-6} alkyl-CO-aryl, arylC_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxyC_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkylC_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonylC_{1-6} alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC_{1-6} alkyl, aryloxy, C_{1-6} alkylsulfonamido, C_{1-6} alkylamido, C_{1-6} alkylsulfonamidoC_{1-6} alkyl, C_{1-6} alkylamidoC_{1-6} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC_{1-6} alkyl, arylcarboxamidoC_{1-6} alkyl, aroyl, aroylC_{1-6} alkyl, arylC_{1-6} alkanoyl, or a group -COR^{15}, -$NR^{15}R^{16}$, -$CONR^{15}R^{16}$, -$NR^{15}COR^{16}$, -$NR^{15}SO_2R^{16}$ or -$SO_2NR^{15}R^{16}$, wherein R^{15} and R^{16} independently represent hydrogen, C_{1-6} alkyl or C_{3-8} cycloalkyl or together may be fused to form a 5- to 7- membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom and optionally substituted by a halogen, C_{1-6} alkyl or -C_{1-6} alkylC_{1-6} alkoxy group;

Z represents a bond, CO, -$CON(R^{10})$- or SO_2, such that when R^1 represents hydrogen, Z represents $CONR^{10}$;

p is 1 or 2;
m, n and r independently represent 0, 1 or 2;
R^2 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl, such that when n represents 2, two R^2 groups may instead be linked to form a phenyl ring;
R^4 represents C_{1-6} alkyl, such that when r represents 2, two R^4 groups may instead be linked to form a CH_2, $(CH_2)_2$ or $(CH_2)_3$ group;
R^{10} represents hydrogen or C_{1-6} alkyl, or R^{10}, together with R^1 forms a heterocyclic group;
R^3 represents $-(CH_2)_q-NR^{11}R^{12}$ or a group of formula (i):



(i)

wherein q is 2, 3 or 4;
R^{11} and R^{12} independently represent C_{1-6} alkyl or C_{3-8} cycloalkyl or together with the nitrogen atom to which they are attached represent an N-linked nitrogen containing heterocyclyl group optionally substituted by one or more R^{17} groups;
R^{13} represents hydrogen, C_{1-6} alkyl, $-C_{1-6}$ alkyl-C_{1-6} alkoxy, C_{3-8} cycloalkyl, $-C_{1-6}$ alkyl-C_{3-8} cycloalkyl, $-C_{1-6}$ alkyl-aryl or heterocyclyl;
R^{14} and R^{17} independently represent halogen, C_{1-6} alkyl, haloalkyl, OH, diC_{1-6} alkylamino, C_{1-6} alkoxy or heterocyclyl;
f and k independently represent 0, 1 or 2;
g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0;
with the proviso that when m represents 1, n and r both represent 0 and R^3 represents $-(CH_2)_3$-N-piperidine or $-(CH_2)_3$-N(ethyl)$_2$, R^1-Z represents a group other than methyl, -CO-O-C$(CH_3)_3$ or benzyl;
and with the proviso that when m, n and r all represent 0, p represents 1, R^3 represents $-(CH_2)_3$-N-pyrrolidine or $-(CH_2)_3$-N-piperidine, R^1 represents benzyl, Z represents a group other than a bond;
and with the proviso that when m, n and r all represent 0, p represents 1, R^3 represents$-(CH_2)_3$-N-piperidine, R^1 represents isopropyl, Z represents a group other than a bond;
and with the proviso that when m represents 1, n and r both represent 0, p represents 1, R^3 represents$-(CH_2)_3$-N-piperidine, R^1 represents methyl, isopropyl, aryl or benzyl, Z represents a group other than a bond;
and with the proviso that when m and n both represent 0, R^3 represents $-(CH_2)_3$-N(ethyl)$_2$, p represents 1, r represents 2 and R^1 and R^4 both represent methyl, Z represents a group other than a bond;
or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to claim 1 which is a compound of formula E1-E503 or a pharmaceutically acceptable salt thereof.

3. (Currently Amended) A pharmaceutical composition which comprises the compound of ~~formula (I) as defined in~~ claim 1 ~~or claim 2~~ or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

4. – 6. (Cancelled)

7. (Currently Amended) A method of treatment of neurological diseases or inflammatory diseases of the upper respiratory tract which comprises administering to a host in need thereof an effective amount of a compound of ~~formula (I) as defined in~~ claim 1 ~~or claim 2~~ or a pharmaceutically acceptable salt thereof.

8. (Currently Amended) A pharmaceutical composition for ~~use in~~ the treatment of neurological diseases or inflammatory diseases of the upper respiratory tract which comprises the compound of ~~formula (I) as defined in~~ claim 1 ~~or claim 2~~ or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

9. (New) A pharmaceutical composition which comprises the compound of claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

10. (New) A pharmaceutical composition for the treatment of neurological diseases or inflammatory diseases of the upper respiratory tract which comprises the compound of claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

11. (New) A method of treatment of neurological diseases or inflammatory diseases of the upper respiratory tract which comprises administering to a host in need thereof an effective amount of a compound of claim 2 or a pharmaceutically acceptable salt thereof.